Buy Epalrestat Powder Raw Drug Diabetic Neuropathies Treatment Online
What is Epalrestat ?
Epalrestat is a carboxylic acid derivative[1] and a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy, which is one of the most common long-term complications in patients with diabetes mellitus. It reduces the accumulation of intracellular sorbitol which is believed to be the cause of diabetic neuropathy, retinopathy and nephropathy.
Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. Unlike the current treatment options for diabetic neuropathy, epalrestat may affect or delay progression of the underlying disease process.
Epalrestat Certificate of Analysis
| Product name |
Epalrestat |
| CAS No. |
82159-09-9 |
Outer Packing |
1kg/bag |
| Production date |
2017.12.17 |
Shelf life |
2019.12.16 |
| Standard adopted |
Enterprise Standard |
| Items of analysis |
Specification |
Results |
| Appearance |
Orange-red crystalline powder with specific odor |
Conforms |
| Meting Point |
222-226℃ |
222-225.5℃ |
| Single impurity |
≤0.5% |
0.21% |
| Total impurities |
≤1.0% |
0.8% |
| Loss in drying |
≤0.5% |
0.15% |
| Assy (hplc) |
≥99% |
99.2% |
| Conclusion |
Qualified |
Epalrestat Effects and Side Effects
Data from experimental studies indicate that epalrestat reduces sorbitol accumulation in the sciatic nerve, erythrocytes, and ocular tissues in animals, and in erythrocytes in humans. Data from six clinical trials were evaluated, and it was determined that epalrestat 50 mg 3 times/day may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms as compared with baseline and placebo.
Epalrestat is well tolerated, and the most frequently reported adverse effects include elevations in liver enzyme levels and gastrointestinal-related events such as nausea and vomiting. Epalrestat may serve as a new therapeutic option to prevent or slow the progression of diabetic neuropathy. Long-term, comparative studies in diverse patient populations are needed for clinical application.
